Compare 10X Genomics Inc (TXG) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Unilever plc — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Unilever plc trades at $62.18 (market cap $131.86B). The key difference: Unilever plc is far larger — about 24.1× 10X Genomics Inc's market cap, and Unilever plc pays a 3.68% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | UL | |
|---|---|---|
Market Cap | $5.48B | $131.86B |
Sector | Health | Consumer Staples |
52-Week High | $45.80 | $74.59 |
52-Week Low | $11.34 | $55.05 |
Enterprise Value | $5.02B | $157.31B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Unilever (UL) trades at $60.79, down 2.56% today, with a mixed technical and fundamental backdrop. The stock shows a bullish technical signal from moving averages but has missed earnings expectations in recent quarters. Revenue in 2024 was $60.76B with a net income margin of 9.45%, while the company explores strategic moves like a potential bid for Thorne and a partnership with Accenture to scale AI in manufacturing.
The outlook is balanced; strong cash flow and a high ROE of 53.32% support the dividend, but recent earnings misses and a high P/B ratio of 7.55 pose risks. Analyst sentiment is neutral with a 51.36% hold rating, reflecting cautious optimism amid execution challenges and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
